BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price decreased by research analysts at Morgan Stanley from $115.00 to $112.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target indicates a potential upside of 37.34% […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.75-2.95 for the period, compared to the consensus estimate of $2.59. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.75 billion. BioMarin Pharmaceutical also updated […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $100.00 to $110.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would suggest a potential […]
Jennison Associates LLC Cuts Stake in BioMarin Pharmaceutical Inc (NASDAQ:BMRN) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They currently have a $110.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 34.47% from the stock’s previous close. Several […]